The Colorado Prescription Drug Affordability Board will be the first state board to consider upper payment limits on prescription medications, including Enbrel, Stelara, and Cosentyx.

While this Board is tasked with making prescription drugs more affordable for patients, these payment limits are likely to reduce prescriber reimbursement and limit patient access.

Join Advocates for Compassionate Therapy Now, International Foundation for Autoimmune & Autoinflammatory Arthritis, Coalition of State Rheumatology Organizations (CSRO), and Colorado Bioscience Association to learn how these new payment limits may impact your practice and your patients.

---

Date & Time:

🗓️ Monday, June 23
🕕 6:00 PM – 7:00 PM MST
📍 Virtual via Zoom

---

Speakers:

• Bridget Dandaraw-Seritt
  Founder, Advocates for Compassionate Therapy Now (ACT Now)

• Tiffany Westrich-Robertson
  CEO, International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis)

• Harry L. Gewanter, MD, FAAP, MACR
  Board of Directors, Coalition of State Rheumatology Organizations (CSRO)

• Amy Berenbaum Goodman
  Vice President & Counsel, Policy + Advocacy, Colorado Bioscience Association

---

Registration:

This webinar is free to attend, but registration is required.

👉 Register here via CSRO’s website
or use the QR code provided in promotional materials.

---

Contact:

📧 For questions, please email: info@csro.info

---